Eris Lifesciences · NSE: ERIS · BSE: 540596
Q4 FY19 results · Jan–Mar 2019
Eris Lifesciences reported revenue from operations of ₹214.82 crore and net profit of ₹53.88 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 214.82 | — | — | 252.40 | −14.9% |
| Other income | 11.73 | — | — | 10.29 | +14.0% |
| Total income | 226.55 | — | — | 262.68 | −13.8% |
| Profit before tax | 58.24 | — | — | 89.11 | −34.6% |
| Net profit for the period | 53.88 | — | — | 80.20 | −32.8% |
| Attributable to shareholders of the company | 54.09 | — | — | 80.14 | −32.5% |
| EPS, basic (₹) | 3.93 | — | — | 5.83 | −32.6% |
| Net margin (%) | 25.1 | — | 31.8 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 198.43 | — | — | 230.80 | −14.0% |
| Other income | 11.60 | — | — | 10.15 | +14.2% |
| Total income | 210.03 | — | — | 240.96 | −12.8% |
| Profit before tax | 59.10 | — | — | 87.27 | −32.3% |
| Net profit for the period | 52.42 | — | — | 78.88 | −33.5% |
| EPS, basic (₹) | 3.81 | — | — | 5.74 | −33.6% |
| Net margin (%) | 26.4 | — | 34.2 |
Consolidated
- Filed with BSE
- 22 May 2019, 15:16 IST
- Board meeting
- 21 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 May 2019, 15:16 IST
- Board meeting
- 21 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE